Neoadjuvant Chemoimmunotherapy HNSCC in Advance...

By João L. Carapinha

March 31, 2025

Could a neoadjuvant chemoimmunotherapy approach redefine care for head and neck cancer? A recently published study (linked below) demonstrated promising outcomes for patients with advanced HPV-negative head and neck squamous cell carcinoma (HNSCC)...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.